P4512
Puromycin
liquid, suitable for cell culture, BioReagent
Synonym(s):
Achromycin, PDH, Stillomycin, Stylomycin
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352207
NACRES:
NA.76
Recommended Products
product name
Puromycin ready made solution, 10 mg/mL in H2O, ≥98% (HPLC), Cell culture tested
Quality Level
Assay
≥98% (HPLC)
form
liquid
concentration
10 mg/mL in H2O
storage temp.
2-8°C
General description
Puromycin is an aminonucleoside antibiotic naturally produced by Streptomyces alboniger as a tyrosyl tRNA analog. It inhibits ribosomal protein synthesis process by causing premature chain termination acting as an analog of the 3′-terminal end of the aminoacyl-tRNA. Puromycin also acts as a reversible inhibitor of dipeptidyl-peptidase II (serine peptidase) and cytosol alanyl aminopeptidase (100μM, IC50=0.6μM). Puromycin is used as a selection marker gene (puromycin-N-acetyltransferase gene, pac) in eukaryotic/mammalian cells.
Puromycin has a wide variety of biological activities with inhibitory effect against bacteria, protozoa, parasitic worms, algae, plants, and mammalian cells.
Puromycin shows broad spectrum activity, particularly strong activity against gram positive microorganisms but weak activity against acid-fast bacilli and even weaker activity against gram negative microorganisms.
Puromycin has anti-cancer properties, inducing apoptosis in breast cancer cells. It has been shown that Puromycin induces apoptosis in MCF-7 breast cancer cells using an immunological assay to study apoptosis (the modulating effect of insulin-like growth factor-1 (IGF-1)). Puromycin at 0.5 microg/ml induced a high level of apoptosis in MCF-7 breast cancer cells, although there was still a non-negligible amount of synthesized protein. The activity of Puromycin was compared to 2 other protein synthesis inhibitors (cycloheximide and emetine), in which apoptosis occurred when protein synthesis was almost completely blocked.
Puromycin also showed antitumor activity in MDA-MB-231 breast cancer cells, causing suppression of 45S pre-ribosomal RNA and upstream binding factor (UBF).
Furthermore, Puromycin was used to study the vascular smooth muscle cell viability after treatment in rabbit model.
Technical information
The suggested concentration of Puromycin in cell culture assays is 0.2-10-μg/mL. Therefore, it is recommended to dilute the ready made solution 1:1000-50,000.
Puromycin has a wide variety of biological activities with inhibitory effect against bacteria, protozoa, parasitic worms, algae, plants, and mammalian cells.
Puromycin shows broad spectrum activity, particularly strong activity against gram positive microorganisms but weak activity against acid-fast bacilli and even weaker activity against gram negative microorganisms.
Puromycin has anti-cancer properties, inducing apoptosis in breast cancer cells. It has been shown that Puromycin induces apoptosis in MCF-7 breast cancer cells using an immunological assay to study apoptosis (the modulating effect of insulin-like growth factor-1 (IGF-1)). Puromycin at 0.5 microg/ml induced a high level of apoptosis in MCF-7 breast cancer cells, although there was still a non-negligible amount of synthesized protein. The activity of Puromycin was compared to 2 other protein synthesis inhibitors (cycloheximide and emetine), in which apoptosis occurred when protein synthesis was almost completely blocked.
Puromycin also showed antitumor activity in MDA-MB-231 breast cancer cells, causing suppression of 45S pre-ribosomal RNA and upstream binding factor (UBF).
Furthermore, Puromycin was used to study the vascular smooth muscle cell viability after treatment in rabbit model.
Technical information
The suggested concentration of Puromycin in cell culture assays is 0.2-10-μg/mL. Therefore, it is recommended to dilute the ready made solution 1:1000-50,000.
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Masaaki Iwamoto et al.
Gene, 534(2), 249-255 (2013-11-05)
A puromycin-N-acetyltransferase gene (pac) is widely used as a selection marker for eukaryotic gene manipulation. However, it has never been utilized for molecular studies in the ciliate Tetrahymena thermophila, in spite of the limited number of selection markers available for
PUROMYCIN INHIBITION OF PROTEIN SYNTHESIS.
M A DARKEN
Pharmacological reviews, 16, 223-243 (1964-09-01)
R Giegé et al.
Current opinion in structural biology, 8(3), 286-293 (1998-07-17)
Mimics recapitulating the structural features of tRNAs are involved in biological processes other than ribosome-dependent protein synthesis. A knowledge of the rules underlying the architecture and function of tRNAs allows the design of non-natural mimics. The study of these mimics
G Söderlund et al.
Neoplasma, 51(1), 1-11 (2004-03-09)
The objective of the following work was to study the apoptosis inducing effect of puromycin in MCF-7 breast cancer cells and compare this effect with cycloheximide and emetine, 2 other inhibitors of protein synthesis. We also wished to investigate if
S de la Luna et al.
Gene, 62(1), 121-126 (1988-01-01)
Recombinant plasmids have been obtained that lead to the accumulation of five- to ten-fold more puromycin-N-acetyl-transferase (PAC) mRNA and two- to three-fold more PAC activity than the already described plasmid pSV2pac [Vara et al., Nucl. Acids Res. 14 (1986) 4117-4124].
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service